BioVie (BIVI) News Today $3.05 -0.06 (-1.93%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period BioVie files to sell 7.71M shares of common stock for holdersNovember 22 at 9:22 PM | markets.businessinsider.comBioVie says Parkinson’s Disease clinical trial is fully fundedNovember 5, 2024 | markets.businessinsider.comBioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully FundedNovember 5, 2024 | theglobeandmail.comBioVie Inc. Announces Closing of Registered Direct OfferingOctober 31, 2024 | tmcnet.comBioVie Raises Capital Through Direct Stock OfferingOctober 30, 2024 | msn.comBioVie Raises $3.24 Million in Direct OfferingOctober 30, 2024 | markets.businessinsider.comBioVie 1.15M share registered direct offering priced at $2.83October 29, 2024 | markets.businessinsider.comUPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq RulesOctober 28, 2024 | globenewswire.comBioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq RulesOctober 28, 2024 | globenewswire.comBioVie Inc. (NASDAQ:BIVI) Short Interest UpdateBioVie Inc. (NASDAQ:BIVI - Get Free Report) saw a large drop in short interest in October. As of October 15th, there was short interest totalling 187,700 shares, a drop of 51.0% from the September 30th total of 383,100 shares. Based on an average daily trading volume, of 4,550,000 shares, the short-interest ratio is currently 0.0 days. Approximately 3.4% of the company's stock are sold short.October 26, 2024 | marketbeat.comBioVie Announces $6 Million Stock Offering and PlacementOctober 25, 2024 | markets.businessinsider.comBioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private PlacementOctober 24, 2024 | globenewswire.comBioVie 2.667M share registered direct offering priced at $2.25October 24, 2024 | markets.businessinsider.comBioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesOctober 23, 2024 | globenewswire.comBioVie Secures $6.66 Million Through Direct OfferingOctober 23, 2024 | markets.businessinsider.comBioVie Announces Stock Offering and Private PlacementOctober 23, 2024 | finance.yahoo.comBioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private PlacementOctober 22, 2024 | globenewswire.comBioVie stock dips after pricing offering to raise $6.66MOctober 22, 2024 | msn.comBioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesOctober 21, 2024 | globenewswire.comTraders Buy Large Volume of Call Options on BioVie (NASDAQ:BIVI)BioVie Inc. (NASDAQ:BIVI - Get Free Report) saw unusually large options trading on Monday. Stock traders acquired 2,043 call options on the company. This is an increase of approximately 2,661% compared to the average daily volume of 74 call options.October 21, 2024 | marketbeat.comBioVie (NASDAQ:BIVI) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comBioVie secures patent for terlipressin formulationOctober 17, 2024 | uk.investing.comBioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of TerlipressinOctober 15, 2024 | globenewswire.comBioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of TerlipressinOctober 2, 2024 | markets.businessinsider.comBioVie Inc. (NASDAQ:BIVI) Sees Large Drop in Short InterestBioVie Inc. (NASDAQ:BIVI - Get Free Report) saw a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 139,800 shares, a drop of 8.3% from the August 31st total of 152,400 shares. Approximately 3.7% of the company's stock are sold short. Based on an average trading volume of 147,700 shares, the short-interest ratio is currently 0.9 days.September 29, 2024 | marketbeat.comBioVie Inc. Announces Closing of Public OfferingSeptember 25, 2024 | globenewswire.comCrude Oil Gains Over 1%; BioVie Shares PlungeSeptember 24, 2024 | benzinga.comWhy BioVie (BIVI) Stock Is Down Over 50% TodaySeptember 24, 2024 | msn.comDow Rises Over 50 Points; AutoZone Posts Downbeat EarningsSeptember 24, 2024 | msn.comBioVie plummets 50%, prices $3M stock offeringSeptember 24, 2024 | msn.comBioVie (NASDAQ:BIVI) Shares Up 1.4%BioVie (NASDAQ:BIVI) Trading Up 1.4%September 24, 2024 | marketbeat.comBioVie Inc. Announces Pricing of Public OfferingSeptember 23, 2024 | globenewswire.comBioVie Inc. Announces Proposed Public OfferingSeptember 23, 2024 | globenewswire.comBioVie secures funding for long COVID drug trialSeptember 18, 2024 | investing.comBioVie Gets Approval For $12.6 Mln Grant To Initiate Phase 2 Trial Of Bezisterim For Long COVIDSeptember 16, 2024 | markets.businessinsider.comBioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVIDSeptember 16, 2024 | globenewswire.comBioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVIDSeptember 3, 2024 | globenewswire.comBioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery MeetingAugust 27, 2024 | globenewswire.comBioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery MeetingAugust 14, 2024 | markets.businessinsider.comBioVie, Inc.: BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's DiseaseAugust 8, 2024 | finanznachrichten.deBioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s DiseaseAugust 8, 2024 | finance.yahoo.comBioVie says FDA aligns with mid-stage Parkinson’s disease trialAugust 8, 2024 | msn.comBioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's DiseaseAugust 8, 2024 | globenewswire.comBioVie Inc. Announces Reverse Stock SplitAugust 6, 2024 | globenewswire.comIndividual investors invested in BioVie Inc. (NASDAQ:BIVI) copped the brunt of last week's US$55m market cap declineAugust 6, 2024 | finance.yahoo.comBioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD CongressJune 20, 2024 | globenewswire.comJoin BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26June 12, 2024 | globenewswire.comBioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease PatientsMay 22, 2024 | finance.yahoo.comBioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease PatientsMay 22, 2024 | globenewswire.comBIVI Jul 2024 0.500 putMay 18, 2024 | nz.finance.yahoo.com Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address 50-year Wall Street legend: “Sell this tech stock NOW” (Ad)Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. BIVI Media Mentions By Week BIVI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIVI News Sentiment▼0.950.49▲Average Medical News Sentiment BIVI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIVI Articles This Week▼13▲BIVI Articles Average Week Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Enlivex Therapeutics News Today Context Therapeutics News Today Alto Neuroscience News Today Rani Therapeutics News Today Journey Medical News Today Vaxart News Today INmune Bio News Today Scilex News Today Century Therapeutics News Today Monopar Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIVI) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIVI Stock Alerts